Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vapendavir in COPD patients with rhinovirus challenge
NCT06149494Phase 2Completed
- Sponsor
- Altesa BioSciences
- Start
- Nov 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rhinovirus infection comparing Vapendavir Cohort with Placebo Cohort (2 cohorts). Primary endpoint: Peak change in Forced Expiratory Volume in 1 Second from baseline at 7 weeks. Started Nov 2023; status: completed.
02
Drugs
Vapendavir
03
Conditions
rhinovirus infection
Beyond the preview
Go deeper on NCT06149494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06149494.